Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Atossa Therapeutics, Inc. - Common Stock (NQ:ATOS)

0.9001 +0.0403 (+4.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atossa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for a dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday morning! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace
7 High-Potential Penny Stocks in the Biotech Sector
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider. 
Via InvestorPlace
Recap: Atossa Therapeutics Q2 Earnings
  Atossa Therapeutics (NASDAQ:ATOS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:30 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyzing Atossa Therapeutics's Unusual Options Activity
Atossa Therapeutics (NASDAQ:ATOS) shares experienced unusu... 
Via Benzinga
3 Best Penny Stocks Under $1 to Buy in April
By their very nature, the best penny stocks under $1 are a huge gamble with potentially huge returns for speculative investors. 
Via InvestorPlace
The 3 Best Biotech Stocks Under $1 to Buy for April
While risky, here are some of the best biotech stocks under $1, with solid catalysts, investors may want to consider. 
Via InvestorPlace
The 3 Best Biotech Stocks Under $1 to Buy for January
Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 49 companies made new 52-week lows. 
Via Benzinga
Why Is NuZee Down By Over 21%: Here Are 38 Stocks Moving Premarket
Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares rose 46% to $6.98 in pre-market trading after jumping around 46% on Friday. The company recently said it expects unaudited... 
Via Benzinga
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Cyren Ltd. (NASDAQ: CYRN) rose 31.1% to $2.32 in pre-market trading after the company entered into an agreement with Content Services Group to sell all equity interests in its legacy secure... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers ContraFect (NASDAQ:CFRX) stock mo... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers ContraFect (NASDAQ:CFRX) stock in... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Tenet Healthcare (NYSE:THC) stock r... 
Via Benzinga
ATOS Stock Holders Should Mark Their Calendars for Oct. 7
Today, investors in Atossa Pharmaceuticals and ATOS stock appear to be cheering a delayed shareholder vote on a stock issuance proposal. 
Via InvestorPlace
Atossa To Conduct Endoxifen Mid-Stage Study In Sweden
Atossa Therapeutics Inc (NASDAQ: ATOS) has received approval from the Swedish Ethics Review Authority to begin a Phase 2 clinical study of oral Endoxifen to reduce... 
Via Benzinga
Atossa Therapeutics Stock Lost Its Covid Mojo, and Its Pipeline Fails To Impress
Atossa’s Covid treatment is too little too late and I am concerned about the market size for Endoxiden. Avoid ATOS stock here. 
Via InvestorPlace
Atossa Therapeutics Has a Steep Climb Ahead of It
Atossa Therapeutics is popular with the Reddit crowd. However, ATOS stock doesn’t make the top 25 on the platform. Should you buy it anyway? 
Via InvestorPlace
Exposures COVID-19
As its Meme Status Has Come and Gone, Skip Out on Atossa Therapeutics Stock
No matter talked about by the Reddit set, despite its heavy short-interest, ATOS stock will likely fall lower rather than get squeezed 
Via InvestorPlace
Exposures COVID-19
Atossa Therapeutics May Look Tempting, but There’s No Reason to Get in Now
ATOS stock has some exciting points, but its story sends a message investors have heard, namely the price of progress is dilution. 
Via InvestorPlace
With Zero Revenue, I Can’t Get Excited About Atossa
ATOS stock surged briefly in 2021 based on several catalysts, but none of them right now is supportive of its current price and valuation. 
Via InvestorPlace
Exposures COVID-19
The Bear Case for Atossa Therapeutics Makes More Sense at This Time
Investors have become wary of the risks surrounding Atossa's pipeline. That caution will continue pulling down ATOS stock. 
Via InvestorPlace
Most Active Equity Options For Midday - Wednesday, Aug. 4
Top Tickers: AMD, AAPL, TSLA, AMC, PFE, NVDA, GM, FB, BABA, MRNA, F, SOFI, HOOD, MU, UBER, BA, ATOS, AMZN, ATVI, NIO. 
Via Talk Markets
88 Biggest Movers From Yesterday
Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in... 
Via Benzinga
Investors Should Avoid High-Risk Atossa Therapeutics
Given the early stages of Atossa's clinical trials, ATOS stock is too risky to get involved with at this point. 
Via InvestorPlace
63 Biggest Movers From Friday
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares surged 55% to close at $6.37 on Friday after the company said the FDA has granted its eryaspase fast track designation for the... 
Via Benzinga
Exposures Product Safety
The Week In Charts: Trading Stuff Part 3 - Trading (Or Not Trading!) OGRes, Russian Dolls, ETFs
A look at lessons learned from active trading of IPOs, ETFs, Russian Dolls, and a discussion on what might be the secret to trading-which ironically, is the polar opposite to trading. 
Via Talk Markets
ATOS Stock: The Big News That Has Atossa Therapeutics Plunging 20% Today
ATOS stock is on its way down today. As the biotech company announces a special shareholder meeting, holders worry about stock dilution. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.